SURF News and Press, Surface Oncology Inc. From 02/24/21

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor microenvironment, today announced that Rob Ross, M.D., incoming chief executive officer, will partic...

Surface Oncology (SURF) has announced that Robert Ross will become the company’s president and chief executive officer with effect from April 1, 2021.Mr. Ross who has served as the company’s chief medical officer since 2016 will also join the company board while the current CEO ...

Experienced clinical development executive to succeed current CEO Jeff Goater, who will become Chairman of the Board Transition effective April 1, 2021 CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology...

Trillium Therapeutics has two lead candidates that encourage immune cells known as “macrophages” to gobble up cancer cells by blocking a protein known as CD47. However, the CD47 inhibitor space is incredibly crowded. There are 10+ groups developing a drug that hits the C...

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will participat...

Click here to read the previous top NASDAQ pharma stocks article. 2020 wasn’t without challenges for the pharmaceutical market, which like other sectors is bound to face lasting impacts from the COVID-19 pandemic. That being said, the major underlying drivers for ...

Indonesia Energy Corporation (INDO) +158%.Conifer Holdings (CNFR) +112%.Bionano Genomics (BNGO) +41%.JanOne (JAN) +40%.Net Element (NETE +38% as Mullen Technologies receives LOI for purchase order of 1,500 MX-05 EV.Hepion Pharmaceuticals (HEPA +35% on announcing positive d...

CNS Pharmaceuticals (CNSP) +62%.Cyclo Therapeutics (CYTH) +47%.Mereo BioPharma Group (MREO) +38% on licensing pact with Ultragenyx.DermTech (DMTK) +23% after announcing topline results from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Le...

Shares of Surface Oncology (NASDAQ: SURF) were down by 13.6% as of 3:32 p.m. EST on Thursday. The decline came after the company announced a deal with GlaxoSmithKline (NYSE: GSK) to license its preclinical program SRF813 for $85 million up front. Surface is also eligible to ...

Surface Oncology (SURF) inks an agreement with GlaxoSmithKline (GSK) for worldwide development and commercial rights to its preclinical program SRF813. Under the terms of the agreement, Surface Oncology will receive an upfront payment of $85M, potential milestone payments of $730M, ...